News
NICE Recommends Isatuximab + POM/Dex for people with difficult-to-treat multiple myeloma
NICE has recommended Isatuximab for people with difficult-to-treat multiple myeloma (MM). Isatuximab, administered as an intravenous infusion, plus pomalidomide and dexamethasone is recommended for use within the Cancer Drugs Fund as an option for treating relapsed...
Hypercalcemia Indicates Poor Outcomes in Newly Diagnosed Multiple Myeloma (NDMM)
A new study published in Cancer Medicine demonstrates that Hypercalcemia is associated with poor rates of survival in patients with newly diagnosed myeloma (NDMM). The researchers retrospectively evaluated the prognostic impact and mechanism of hypercalcemia in 357...
Accurate Identification of Patients with SMM at Highest Risk of Developing MM Remains Difficult
The accurate identification of patients with SMM at highest risk of developing MM remains difficult.
FDA Lifts Clinical Hold on MELANI-01 Study Evaluating UCARTCS1
Cellectis announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on the Phase 1 MELANI-01 trial evaluating the UCARTCS1 product candidate for the treatment of patients with relapsed or refractory multiple myeloma (MM). Cellectis worked...
Once-weekly Regimen of Selinexor, Bortezomib, and Dexamethasone Slows Progression of RRMM
A once-weekly regimen of selinexor, bortezomib, and dexamethasone slows the progression of relapsed or refractory multiple myeloma, according to a study published in the Nov. 14 issue of The Lancet. The results from the BOSTON study demonstrate that the once-weekly...
GSK to Measure Minimal Residual Disease with clonoSEQ, Adaptive Biotechnologies’ next-generation sequencing assay
GlaxoSmithKline plc (GSK) to use its clonoSEQ® Assay to assess minimal residual disease (MRD) in GSK’s portfolio of hematology products. MRD is increasingly used as an endpoint in clinical trials, and clonoSEQ has emerged as the premier test to reliably and accurately...
Featured Content
Overview of Key Early-phase CAR T-cell Therapy Studies in Relapsed or Refractory Multiple Myeloma
In this article, we look at some of the early-phase clinical trials, where chimeric antigen receptor (CAR) T-cell therapy has been targeted to the B-cell maturation antigen (BCMA) in patients with relapsed or refractory MM (RRMM). The anti-BCMA CAR T-cell...
What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...
Join Our Community
By joining the MYELOMA360 community, you will receive regular updates with news, information, insights and expert opinions.
Of course, you can opt out at any time.